NEW YORK ─ Unilabs and Ibex Medical Analytics have inked an agreement to implement Ibex’s artificial intelligence-based Galen platform in European pathology labs, starting in Sweden and later to 16 other countries.
Geneva-based Unilabs said it is deploying Ibex’s multi-tissue AI-based platform to facilitate prompt, targeted cancer treatment when it is most needed.
Financial and other terms of the agreement were not disclosed.
Using algorithms developed with advanced machine learning, the Galen platform is trained to detect cancers and provide other clinical findings. Its algorithms automatically analyze images from tissue biopsies, providing insights to pathologists that include case prioritization worklists, cancer heat maps, tumor grading and measurement, and streamlined reporting tools.
The firms added that the platform also helps pathologists improve the quality of cancer diagnosis, implement real-time quality control, reduce diagnosis time, and boost productivity.
The Galen platform is CE marked for breast and prostate cancer detection in multiple workflows and was recently granted Breakthrough Device Designation by the US Food and Drug Administration.
In March, digital pathology firm Proscia and Tel Aviv, Israel-based Ibex said they agreed to combine their respective technologies into an integrated product for artificial intelligence-based prostate cancer diagnosis.